Q-VANT and SPI Pharma Offering Broader Access to Sustainable and Scalable Pharma-grade Saponin Adjuvants Press Q-VANT and SPI Pharma Offering Broader Access to Sustainable and Scalable Pharma-grade Saponin Adjuvants
Q-VANT Biosciences enters Vaccine Research Master Agreement with Kansas State University Teams to Study the Impact of Saponin Adjuvants on Animal Vaccine Efficacy Press Q-VANT Biosciences enters Vaccine Research Master Agreement with Kansas State University Teams to Study the Impact of Saponin Adjuvants on Animal Vaccine Efficacy
Q-Vant Biosciences Announces Positive Study Results for Its Sustainable Quillaja-Based Vaccine Adjuvant, Q-VET-S®, in Kansas State’s Classic Swine Fever Vaccine Press Q-Vant Biosciences Announces Positive Study Results for Its Sustainable Quillaja-Based Vaccine Adjuvant, Q-VET-S®, in Kansas State’s Classic Swine Fever Vaccine
Q-VANT Biosciences Launches to Solve the Pharmaceutical Industry Problem of Limited Quillaja Saponin Adjuvants for Life-Saving Vaccines Press Q-VANT Biosciences Launches to Solve the Pharmaceutical Industry Problem of Limited Quillaja Saponin Adjuvants for Life-Saving Vaccines
